7705-63-7

Usage

Uses

Used in Organic Synthesis:
4-(BromoMethyl)phenyl phenyl sulfone is utilized as a reagent and intermediate in various organic synthesis reactions. Its unique structure and reactivity make it a valuable component in the creation of complex organic molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 4-(BromoMethyl)phenyl phenyl sulfone is employed as a key intermediate in the synthesis of various drugs. Its properties allow for the development of new medicinal compounds with potential therapeutic benefits.
Used in Agrochemicals:
4-(BromoMethyl)phenyl phenyl sulfone also finds application in the agrochemical sector, where it serves as an intermediate in the production of pesticides and other agricultural chemicals, contributing to enhanced crop protection and yield.
Used in Materials Science:
Within the field of materials science, 4-(BromoMethyl)phenyl phenyl sulfone is leveraged for its unique properties to develop new materials with specific characteristics, such as improved thermal stability or chemical resistance.
Used in Polymer Chemistry:
In polymer chemistry, 4-(BromoMethyl)phenyl phenyl sulfone is used as a monomer or a modifier to create polymers with tailored properties. Its incorporation can lead to polymers with novel functionalities and improved performance in various applications.
Overall, 4-(BromoMethyl)phenyl phenyl sulfone's versatility and wide-ranging applications make it an essential compound in organic chemistry and across multiple industrial processes.

InChI:InChI=1/C13H11BrO2S/c14-10-11-6-8-13(9-7-11)17(15,16)12-4-2-1-3-5-12/h1-9H,10H2

Upstream product

• 640-57-3 phenyltolylsulfone 
• 7705-64-8 4-(phenylsulfonyl)benzyl alcohol 
• 37991-83-6 4-(phenylsulfonyl)benzoyl chloride 

Downstream Products

• 107822-70-8 (4-benzenesulfonyl-benzyl)-triphenyl-phosphonium; bromide 
• 138384-50-6 N⁶-<4-(phenylsulfonyl)benzyl>-6-aminobenzindol-2(1H)-one 
• 138384-73-3 N⁶-<4-(phenylsulfonyl)benzyl>-6-amino-5-methylbenzindol-2(1H)-one 
• 138814-54-7 6-(acetylamino)-7-nitro-N-<4-(phenylsulfonyl)benzyl>-1,2,3,4-tetrahydroquinoline 
• 7705-68-2 (4-(phenylsulfonyl)phenyl)methyl methyl ether 
• 7705-67-1 2,3-Bis-<4-benzolsulfonyl-phenyl>-propionsaeure-methylester 
• 7718-66-3 4-Benzolsulfonyl-benzyljodid 
• 640-57-3 phenyltolylsulfone 
• 21713-63-3 methyl dibenzylphosphinate 
• 138384-72-2 N⁶-<4-(phenylsulfonyl)benzyl>-N⁶-methyl-6-aminobenzindol-2(1H)-one 
• 138385-07-6 N-<4-(phenylsulfonyl)benzyl>-N-methyl-6-aminobenzindol-2(1H)-thione 
• 138384-52-8 N⁶-methyl-N⁶-<<4-(phenylsulfonyl)phenyl>methyl>-6-aminobenzindole-2,6-diamine 
• 138385-05-4 N⁶-<4-(phenylsulfonyl)benzyl>-N⁶-methyl-2-(methylthio)-6-aminobenzindole 

Relevant academic research and scientific papers

Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant

Due to the emergence of highly pathogenic and oseltamivir-resistant influenza viruses, there is an urgent need to develop new anti-influenza agents. Herein, five subseries of oseltamivir derivatives were designed and synthesized to improve their activity toward drug-resistant viral strains by further exploiting the 150-cavity in the neuraminidases (NAs). The bioassay results showed that compound 21h exhibited antiviral activities similar to or better than those of oseltamivir carboxylate (OSC) against H5N1, H5N2, H5N6, and H5N8. Besides, 21h was 5- to 86-fold more potent than OSC toward N1, N8, and N1-H274Y mutant NAs in the inhibitory assays. Computational studies provided a plausible rationale for the high potency of 21h against group-1 and N1-H274Y NAs. In addition, 21h demonstrated acceptable oral bioavailability, low acute toxicity, potent antiviral activity in vivo, and high metabolic stability. Overall, the above excellent profiles make 21h a promising drug candidate for the treatment of influenza virus infection.

Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof

The invention relates to compounds of formula (I) wherein the groups have stated meanings, and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

DIARYLSULFONES AS 5-HT2A ANTAGONISTS

Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.

ARYLSULFONYL BENZYL ETHERS AS 5-HT2A ANTAGONISTS

Compounds of formula (I) are potent and selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of various CNS disorders.

Substituted isothiazolones

This invention is directed to a compound of Formula (I): and pharmaceutically acceptable forms thereof useful as inhibitors of cPLA2 and a method for preventing, treating or ameliorating a cPLA2 mediated inflammatory related disease, disorder or condition using a compound of Formula (I) and, more particularly, for preventing, treating or ameliorating a cPLA2 mediated inflammatory related disease, disorder or condition which results from the cellular secretion of TXB2 or LTB4.

Crystal-Structure-Based Design and Synthesis of Benzindole-Containing Inhibitors of Thymidylate Synthase

The X-ray crystal-structure-based design, synthesis, and biological activity of a novel family of benzindole-containing inhibitors of thymidylate synthase (TS) are described.The structure-activity of the lead compound was studied by conceptually dividing the molecule into four regions and independently optimizing the substituents for each region.Combination of favored substituents for each region led to inhibitors with Ki's against the human enzyme in the range of 10-20 nM.Thymidine shift experiments suggested that the cytotoxic properties of the best enzyme inhibitors were due to TS targeting in cells.The inhibitors were synthesized from substituted 6-aminobenzindol-2(1H)-ones by alkylation with both a simple alkyl group and a substituted benzylic portion.The 2,6-diaminobenzindoles were prepared from the corresponding lactams by conversion to the thiolactam, alkylation to the methylated thiolactam, and then displacement with a substituted or unsubstituted amine.